Amgen Archives - Vista Partners LLCVista Partners LLC

Amgen’s Quarterly Results Show Surge In Sales & Profit – $AMGN $DIA $IBB $LTRN

Amgen (AMGN) has reported increased quarterly profit driven by robust sales of treatments for conditions like cholesterol and osteoporosis, among other drugs. The biotech firm, which has slightly adjusted its expectations for full-year revenue and profit upwards, has noted that it anticipates the Ho...

Aug 31, 2023 View Article

Amgen Sues Novartis Subsidiary Sandoz Over Alleged Patent Infringement – $AMGN $NVS $XBI $IBB

Reportedly, Amgen Inc. (AMGN) has taken legal action against Sandoz, a subsidiary of Novartis AG (NVS), in New Jersey federal court. The healthcare giant has accused Sandoz of violating several patents by creating biosimilar versions of its profitable bone-strengthening drugs, Prolia and Xgeva. Am...

May 05, 2023 View Article

Amgen Appeals To Supreme Court To Revive Repatha Patents – $AMGN $DIA $IBB $XB $SNY $REGN $INVO

Reportedly, in the coming week, the U.S. Supreme Court will hear Amgen Inc's appeal to revive patents for its Repatha cholesterol-lowering drug. This comes after a lower court invalidated two of Amgen's patents in a legal dispute with Sanofi SA (SNY)) and Regeneron Pharmaceuticals Inc. (REGN) Amgen ...

Apr 04, 2023 View Article

Amgen Increasing Job Cuts Amid Industry Pressure – $AMGN $DIA $INVO

According to reports, Amgen Inc. (AMGN) has declared that it will cut 450 jobs, which accounts for less than 2% of the company's entire workforce. This is the second time this year that the company is implementing layoffs due to the challenges of increasing drug prices and inflation. The decision to...

Mar 22, 2023 View Article

Amgen Declares $2.13 Per Share Dividend For Q2 2023 – $AMGN $DIA $INVO

Reportedly, Amgen (AMGN) has announced that its Board of Directors has approved a dividend of $2.13 per share for the second quarter of 2023. The dividend is scheduled to be paid on June 8, 2023, to all stockholders who are recorded as of the close of business on May 18, 2023. DID YOU KNOW? Fert...

Mar 13, 2023 View Article

Amgen Quarterly Earnings Comes In Below Estimates – $AMGN $DIA $LLY $INVO

Reportedly, Amgen Inc. (AMGN) quarterly earnings were slightly below estimates as a 4% increase in sales of its own drugs was outweighed by lower revenue from its deal with Eli Lilly and Co to manufacture COVID-19 antibody treatments. In 2020, Amgen partnered with Lilly to increase the supply of its...

Feb 08, 2023 View Article

Biopharmaceutical Behemoth Amgen To Host Q4 & Full Year Earnings On Jan 31 – $AMGN $DIA $ATOS

Reportedly, American multinational biopharmaceutical Amgen (AMGN) has scheduled to release its full year 2022 & fourth quarter earnings on January 31, 2023, Tuesday after the close of regular trading hours. The earnings release will be followed by a conference call hosted by CEO & Chairman R...

Jan 30, 2023 View Article

Dow 30 Component Amgen Increases Quarterly #Dividend By 10% – $AMGN $IBB $ATOS

Reportedly, the board of biotech behemoth Amgen (AMGN) announced a $2.13 per share dividend for the first quarter of 2023, payable on March 8, 2023, to all stockholders as of February 15, 2023. The dividend represents a 10% increase from its previous four quarters. If you liked this story ple...

Dec 14, 2022 View Article

Amgen Announces Acquisition Of Horizon Therapeutics For $26.4B – $AMGN $HZNP $XBI $ATOS

Reportedly, Amgen (AMGN) is set to acquire rare disease drugmaker Horizon Therapeutics Plc (HZNP) for $26.4B. Amgen will pay $116.50 in cash for each Horizon share held, or a premium of nearly 20% to the stock's last close. The offer values Horizon at $28.3 billion, including debt. The deal will ad...

Dec 14, 2022 View Article

Biotech Giant Amgen’s Experimental Obesity Drug Shows ‘Promising’ Trends – $AMGN $DIA $ATOS

As per reports, Biotech giant Amgen Inc.'s (AMGN) experimental obesity drug currently known as AMG133 displayed promising durability trends in an early trial, leading way for a larger mid-stage study due early next year. Phase, I trial showed that those administered with the highest tested dose of t...

Dec 12, 2022 View Article

Janssen To Sue Amgen Over Marketing Plans For Similar Drug To Its $9.1B Stelara – $JNJ $AMGN $DIA $ATOS

As per reports, the Janssen unit of Johnson & Johnson (JNJ) has sued healthcare giant Amgen Inc as the latter plans to market drugs for ulcerative colitis and conditions similar to J&J's top-selling drug Stelara. Last year, Stelara generated $9.1 billion of the company's $52 billion in globa...

Dec 06, 2022 View Article

Amgen To Webcast Investor Call On Dec 5 At #WCIRDC2022 – $AMGN $DIA $ATOS $INVO

As per reports, Amgen (AMGN) is to host a webcast call for the investment community at 8:00 a.m. ET on Monday, Dec. 5, 2022, in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC). The webcast can be reached at www.amgen.com, under Investors. ...

Dec 02, 2022 View Article

Amgen Reports Stronger Quarter Profits Recording Volume Growth – $AMGN $DIA $ATOS $INVO

Reportedly, Biotechnology company and Dow 30 component Amgen Inc's (AMGN) third-quarter revenue rose 1% as higher volume growth for its cancer, rheumatology, and cardiovascular products were offset by lower prices and foreign exchange losses. Revenue for the quarter totaled $6.7 billion, exceeding W...

Dec 01, 2022 View Article

Amgen To Webcast Third-Quarter Earnings – $AMGN $DIA $INVIO

Reportedly, healthcare giant Amgen (AMGN) is to release its third-quarter earnings on November 3, 2022, after the market closes. The release will be followed by a conference call with the investment community to discuss the results at 1:30 p.m. PT. The call will be hosted by the chairman and CEO Rob...

Nov 02, 2022 View Article

Biotech Giant Amgen Completes The Acquisition Of ChemoCentryx – $AMGN $JNJ $DIA $ATOS

As per reports, Amgen (AMGN) has successfully acquired ChemoCentryx, Inc. (CCXI), for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. A biopharmaceutical company, ChemoCentryx, Inc is focused on orally-administered methods to treat cancer, inflammato...

Oct 26, 2022 View Article

Amgen’s Lumakras Pill Reduces Risk Of Lung Cancer Progression By 34% In Clinical Trial -$AMGN $DIA $ATOS

Reportedly, Amgen Inc.'s (AMGN) Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial. Amgen is also testing whether the drug could be effective against lung cancer earlier in the disease, and informed that a...

Sep 29, 2022 View Article

Amgen Releases Earnings For June Quarter – Reduces 2022 Revenue Projections – $AMGN $DIA

Amgen (AMGN) reported quarterly earnings this week, reporting adjusted earnings at 163% higher to $4.65 a share, and exceeding expectations for $4.39. Overall sales inched 1% ahead during the June quarter, to $6.59 billion. Sales of Amgen's medicines increased 3% versus the same three months last...

Aug 12, 2022 View Article

Amgen’s Acquisition Of ChemoCentryx To Add Potential Blockbuster Drug To Its List – $AMGN $CCXI $ATOS $DIA

As per reports, Amgen Inc is to acquire ChemoCentryx Inc for $3.7 billion to gain access to a potential blockbuster treatment, Tavneos for inflammatory disorders. The U.S drug maker is to pay $52 in cash for each share of ChemoCentryx. Approved last year, Tavneos is used to treat patients with vasc...

Aug 29, 2022 View Article

Michael V. Drake Appointed To The Board Of Amgen – $AMGN $ATOS $IBB $XBI

Reportedly, Amgen (AMGN) announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately. Dr. Drake will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee. Following the appointm...

Aug 23, 2022 View Article

Dow 30 Component Amgen To Pay Q3 Dividend On Sep 8th – $AMGN $DIA

As per reports, the board of Dow 30 component Amgen (AMGN) declared a $1.94 per share dividend for Q3 2022, payable on September 8, 2022. The dividend is payable to all shareholders as of August 18, 2022. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Fr...

Aug 12, 2022 View Article

Amgen To Report Second Quarter Earnings On Aug 4 – $AMGN $DIA

As per reports, Amgen (AMGN) announced that it will report its second quarter financial results on Thursday, August 4, 2022, after trading closes. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT. Participating in the call from Amgen will be Robe...

Aug 03, 2022 View Article

Amgen’s Lumakras/Immunotherapy Combo Data Results Decision Due Aug 7 – $AMGN $DIA

Reportedly, early trial data on Amgen Inc's (AMGN) Lumakras was released by the World Conference on Lung Cancer (WCLC), but it has been decided that it will hold until Aug. 7 by the meeting organizers from a highly anticipated study in combination with drugs that help the immune system attack cancer...

Jul 19, 2022 View Article

Biotech Giant Amgen Post Quarterly Beat, However… – $AMGN $DIA

Amgen reported a strong quarter with sales increasing 6% to $6.24 billion and exceeding expectations at $6.07 billion. Earnings also came in above projections at $4.25 per share, up 15% on a year-over-year basis. Amgen's osteoporosis treatment Evenity and migraine drug Aimovig reported strong growt...

Apr 29, 2022 View Article

Amgen Due To Release Q1 Earnings Wednesday, April 27, 2022 – $AMGN $DIA

Reportedly, Amgen (AMGN) is to release its first-quarter earnings on Wednesday, April 27, 2022, after the market closes, followed by a conference call with the chairman and CEO Robert A. Bradway, the investment community, and other members of the company's senior management team at 2:00 p.m. PT. Liv...

Apr 26, 2022 View Article

Amgen Contemplates Further Issuance of Green Bonds- $AMGN $DIA

Reportedly, Pharmaceutical giant Amgen Inc. (AMGN) is planning to sell more bonds to benefit the environment and society after its debut green bond was received well by investors. Amgen raised $4 billion in February in a four-part transaction including a $750 million green-bond tranche, a first for ...

Apr 08, 2022 View Article

Amgen To Pay Q2 2022 Dividend On June 8 – $AMGN $DIA

Reportedly, the board of Amgen (AMGN) has announced a $1.94 per share dividend for the second quarter of 2022, payable June 8, 2022, to all shareholders of record as of May 17, 2022. If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners...

Mar 06, 2022 View Article

Amgen’s Q4 Earnings Report Confirms Increase in Revenues – $AMGN $DIA

Reportedly, Amgen (AMGN) released Q4 revenue reporting a 3% increase driven by the sales of a COVID-19 antibody treatment it has partnered with Eli Lilly and Co. (LLY). However, sales its of own legacy drugs dropped 1%, amid pricing pressure from lower-cost competition. The Dow 30 component reporte...

Feb 08, 2022 View Article

AstraZeneca-Amgen Drug For Severe Asthma Gains U.S. FDA Approval

As per reports, the U.S. Food and Drug Administration has approved AstraZeneca (AZN) and Amgen's (AMGN) asthma drug, Tezspire, to treat severe asthma for those aged 12 years and above. The approval comes based on late-stage trial data that shows the drug cut the rate of asthma attacks by 56% among p...

Dec 23, 2021 View Article

Biotech Giant Amgen Releases Q3 Earnings

Amgen (AMGN) reported a 4% rise in quarterly revenue, as pandemic restrictions eased reporting adjusted earnings per share for the quarter of $4.69, beating the average analyst forecast of $4.27. Amgen's net earnings dropped 3% to $3.31 per share with a $400 million licensing-related expense from a ...

Nov 05, 2021 View Article

Biotech Giant Amgen Announces Q4 Dividend Payable Dec 8

As per reports, the board of Dow 30 Amgen (MGN) announced a $1.76 per share dividend for the fourth quarter of 2021 and is payable December 8, 2021 to all stockholders as of November 16, 2021. If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista ...

Oct 27, 2021 View Article

Biotech Giant Amgen Makes Investment In Precision Medicines for Brain Diseases Focused Neumora Therapeutics

As per reports, U.S. biotech giant, Amgen In. (AMGN), has made a $100-million equity investment in Neumora Therapeutics, and simultaneously is allowing Neumora to obtain the global rights to develop and sell certain of Amgen's experimental drugs for neurodegenerative diseases. Neumora Therapeutics, ...

Oct 08, 2021 View Article

Amgen Adds S. Omar Ishrak, Former Chairman & CEO of Medtronic, To Board Of Directors

Reportedly, Amgen (AMGN) has appointed S. Omar Ishrak to its Board of Directors, effective July 30, 2021. Dr. Ishrak will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Compensation and Management Development Committee. The Board now consists of 12 di...

Aug 08, 2021 View Article

Amgen Beats Q2 Estimates – Adjusts Outlook

Reportedly, Amgen exceeded Q2 estimates reporting $4.38 per share, minus some items, on $6.53 billion in sales. Earnings increased 4% year over year and exceeded analysts' estimate for $4.09 per share. Sales topped expectations for $6.46 billion and increased 5%. Across all medicines, volumes grew 8...

Aug 04, 2021 View Article

Amgen – AstraZeneca Asthma Drug Granted Speedy FDA Review

Reportedly, Amgen (AMGN) and AstraZeneca's (AZN) experimental asthma drug tezepelumab has been granted a speedy review by the U.S. Food and Drug Administration for potential approval. The drug displayed promising results to reduce asthma attacks in patients with uncontrolled and severe forms of th...

Jul 12, 2021 View Article

Amgen Lung Cancer Drug Sotorasib With Specific Mutation Gains FDA Approval

Reportedly, Amgen Inc.'s (AMGN) drug sotorasib for non-small cell lung cancer with a specific mutation in a gene known as KRAS in patients whose disease has worsened after treatment with chemotherapy or other medicines gained approval from the U.S. Food and Drug Administration. Sotorasib, to be sol...

May 31, 2021 View Article

Amgen Reports Disappointing Q1 Earnings

Amgen (AMGN) reports disappointing q1 earnings, with earnings declining 12% to $3.70 per share. Sales dropped 4% to $5.9 billion. Amgen's highest selling, an inflammatory treatment called Enbrel reported $924 million, a 20% decline and missed forecasts for nearly $1.1 billion. The company noted sea...

Apr 29, 2021 View Article

Amgen Schedules To Report Q1 Financials Tuesday, April 27

As per reports, Amgen (AMGN) will announce its first-quarter financial results tomorrow, Tuesday, April 27, 2021, after the market closes. A conference call will be held with the investment community at 2:00 p.m. PT following the results. Robert A. Bradway, chairman, & CEO, along with the member...

Apr 26, 2021 View Article

Amgen Completes Acquisition Of Five Prime Therapeutics

Reportedly, Amgen (AMGN) has successful completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics for $38 per share in cash. Five Prime Therapeutics is a clinical-stage biotechnology company working on developing immuno-oncology and...

Apr 20, 2021 View Article

Amgen Announces Acquisition Of Rodeo Therapeutics Corporation

As per reports, Amgen Inc. (AMGN) has reached an agreement to acquire Rodeo Therapeutics Corporation, a Seattle-based privately-held biopharmaceutical company that develops small-molecule therapies focused to promote the repair and regeneration of multiple tissues. As per the terms of the deal, Amg...

Apr 07, 2021 View Article

Amgen Buys Five Prime Deal For $1.9B Boosting Its Cancer Pipeline

As per reports, Amgen Inc. (AMGN) will buy Five Prime Therapeutics Inc. for $1.9 billion in cash that will add new cancer therapies to the pharmaceutical giant’s pipeline. Amgen will pay $38 a share for Five Prime, the transaction is expected to close by the end of the second quarter. South San F...

Mar 08, 2021 View Article

AstraZeneca-Amgen Asthma Drug Shows Promising Results

Reportedly, Amgen's (AMGN) and AstraZeneca's (AZN) experimental drugs have proven to reduce asthma attacks in patients with uncontrolled and severe forms of the respiratory condition in a large study. The medicine, tezepelumab, cut the rate of asthma attacks by 56% among patients when compared to p...

Mar 04, 2021 View Article

Amgen Releases Q4 Earnings – Lowers 2021 Outlook Below Estimates

U.S. biotech, Amgen (AMGN) announced a higher-than-expected profit for the fourth quarter reporting adjusted earnings per share of $3.81 beating the analyst estimate by 41 cents. Net profit for the quarter dropped 3% to $2.76 per share. Revenue increased 7% to $6.6 billion. Sales of rheumatoid arthr...

Feb 08, 2021 View Article

Amgen Announces Seven-Year Environmental Sustainability Plan

As per reports, Amgen (AMGN) has announced its new seven-year environmental sustainability plan 2027 with a commitment to achieve carbon neutrality along with a reduction in water use by 40% and waste disposal by 75%. Since 2007, Amgen has achieved a 33% reduction in carbon emissions, a 30% reducti...

Jan 13, 2021 View Article

All Amgen Articles